Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Assay Development, small molecule HTS and Hit To Lead services

Product Description

Hybrigenics offers full and customized drug discovery services to identify small molecules modulating protein interactions and to optimize them.

We have a strong expertise in protein-protein interactions small molecule screening with more than 40 assays developed. We also offer assays targeting enzymatic activities (eg: proteases, kinases).
 
You can choose to screen our generalist library of 100,000 diverse compounds (or a subset of it) or our natural compound library composed of 2,000 pure compounds and 40,000 enriched plant extracts. The screening steps comprise the identification, confirmation and analytical validation of primary hits.

Otherwise, we can also screen your own library and even transfer the assay to you.

Several hit to lead services are also available:
- Analoging
- Compound Evaluation
- Secondary Assay Development and Screening
- Structure-Analysis Relationship (SAR) Analysis

Our offer is flexible:  we take care of your project at any step from assay development to hit characterization.

For more details, please go to:
http://www.hybrigenics-services.com/contents/our-services/inhibit/assay-development
http://www.hybrigenics-services.com/contents/our-services/inhibit/high-throughput-screening
http://www.hybrigenics-services.com/contents/our-services/inhibit/hit-to-lead-services




Product Assay Development, small molecule HTS and Hit To Lead services
Company Hybrigenics Services SAS
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Hybrigenics Services SAS
3-5 Impasse Reille 75014 Paris France

Tel: +33 (0)1 58 10 38 29
Fax: +33 (0)1 58 10 38 48
Email: services@hybrigenics.com



Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!